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INTRODUCTION: 
In GPSP (Good Post-marketing Study Practice), the investigator must 
conduct drug use-results surveys according to the post-marketing survey 
protocol with the pre-planned sample size. In almost all post-marketing 
survey protocols in Japan, the sample size was determined by n=3/λ for an 
anticipated risk λ (Machin D. et. al 2009). However, this approach 
accommodates for detection of unknown ADR (Adverse Drug Reaction). 
In general, there are three objectives for conducting  a drug use-results 
survey,
1) To detect unknown ADR
2) To evaluate the magnitude of risk of known ADRs
3) To evaluate the factors which affect efficacy and safety of the durg
In this study, we propose an sample size estimation method for determining 
the risk of  known ADRs.
Objectives:
1) Propose an alternative approach of sample size estimation for 
determining the risk of ADR in the post-marketing study.
2) Investigate the required sample sizes in typical cases.
Proposed Sample Size Estimation Approach:
On the label of drugs, the risk of ADR was often classified into three 
categories; (a) <1%, 1% - 5%, >= 5% or (b) <0.1%, 0.1% - 1%, >=1%. It is 
clinically useful if the risk of ADR was clearly classified according to the 
above categories. 
In our approach, when we use the category (a), the sample size is determined 
based on binomial distributions to meet the following conditions:
Pr(r < 1% | λ=5%) < 1% and Pr(r >= 5% | λ=1%) < 1% 
where r is the observed risk, and λ is the true risk. 
Pr(r < 1% | λ=5%) and Pr(r >= 5% | λ=1%) were called the classification error 
probability  in our approach. A scheme of the classification error probability 
was shown in Figure 1.
Applied example:
We applied our approach to  the two cases of the category of (a) <1%, 1% -
5%, >= 5% and (b) <0.1%, 0.1% - 1%, >=1%.
For the category (a), CEP and required sample size n was shown in Figure 2. 
Pr(r < 1% | λ=5%) = 0.00997 and the required sample size was 130. And the 
results of the category (b) was shown in Figure 3. Pr(r < 0.1% | λ=1%) = 
0.00992 and the sample size was 459.
Table 1 showed comparison of required sample sizes of our approach with 
that of  other risk assessment approaches; to detect unknown ADR approach 
and test-based approach. On the test-based approach, we assumed a test of a 
binomial proportion using the normal approximation and a variance estimate 
based on the null proportion with a one-sided significance level of 0.05. 
If true risk was 1%, required sample size of to detect unknown ADR 
approach was 300 and that of the test-based approach with power 95% was 
562. On the other hand, our proposed approach with 1% upper threshold and 
0.1% lower threshold was 459.
Discussion: 
Our approach was focused on the control of classification error probability. This 
feature was clinically useful for discrimination of high risk and low risk.
To discriminate the risk of larger than 5% and the risk of less than 1%, the sample 
size of 130 was adequate. On the other hand, to discriminate the risk of larger than 
1% and the risk of less than 0.1%, the sample size of 459 is needed. In the rare 
ADRs, the more sample size is needed to discrimination.
The required sample sizes of test-based approach with 1% true risk and 95% power 
was 575. And our approach with 1% upper threshold and 0.1% lower threshold was 
459. These figures were larger than that of to detect unknown ADR approach with 
1% true risk, and smaller than that with 0.1% true risk. This means that very large 
sample size is needed to detect low risk, but moderate sample size is adequate to 
discriminate high risk and low risk. 
In general, it is difficult to evaluate the risk of ADR in a specific subgroup for 
example patients with severe liver disease etc. Our approach was useful for 
evaluating the risk of ADR in such subgroups because the required sample size was 
small.
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n= 60
CEP=0.00312
n= 130
CEP=0.00997
n= 200
CEP=0.00113
n= 459
CEP=0.00997
Figure 2:
Classification error probability (CEP) and threshold of number of ADR in the category 
of <1%, 1%-5%, >5%; Pr(r > 5% | λ=1%) = 0.00312, n=60 (left), and Pr(r < 1% | 
λ=5%) = 0.00997, n=130 (right). The required sample size was estimated 130. 
Figure 3:
Classification error probability (CEP) and threshold of number of ADR in the category 
of <0.1%, 0.1%-1%, >1%; Pr(r > 1% | λ=0.1%) = 0.00113, n=200 (left), and Pr(r < 
0.1% | λ=1%) = 0.00997, n=459 (right). The required sample size was estimated 459. 
Pr(r < 1% | λ=5%) and Pr(r >= 5% | λ=1%) were calculated by the 
following formulas. 
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Table 1: Comparison of risk assessment approaches
n=130
<1% 1% - 5% >5%
Classification 
Error 
Probability
Figure 1:  A Schema of the classification error probability
